Vittomo Pengo

Summary

Affiliation: University of Padova
Country: Italy

Publications

  1. ncbi request reprint Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Centre, University of Padova School of Medicine, Ex Busonera Hospital, Via Gattamelata 64, I 35128 Padova, Italy
    Thromb Res 120:127-33. 2007
  2. ncbi request reprint The diagnosis of the antiphospholipid syndrome
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Center, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy
    Pathophysiol Haemost Thromb 35:175-80. 2006
  3. ncbi request reprint Sex and anticoagulation in patients with idiopathic venous thromboembolism
    Vittorio Pengo
    Department of Cardiothoracic and Vascular Sciences, University of Padua 35128, Italy
    Lancet 368:342-3. 2006
  4. ncbi request reprint Monitoring oral anticoagulants: new strategies for an emerging problem
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    Intern Emerg Med 1:3-4. 2006
  5. ncbi request reprint The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism
    James D Douketis
    McMaster University, Hamilton, Ontario, Canada
    Ann Intern Med 147:766-74. 2007
  6. doi request reprint Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile
    V Pengo
    Clinical Cardiology, Thrombosis Center, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    J Thromb Haemost 11:1527-31. 2013
  7. doi request reprint Investigational anticoagulants for hematological conditions: a new generation of therapies
    Gentian Denas
    Padua University Hospital, Cardiology Clinic, Department of Cardiac, Thoracic, and Vascular Sciences, Via Giustiniani 2, 35128 Padova, Italy 390498215658 390498215658
    Expert Opin Investig Drugs 22:1281-94. 2013
  8. doi request reprint Correct laboratory approach to APS diagnosis and monitoring
    V Pengo
    Department of Cardiac, Thoracic and Vascular Sciences, University of Padova Medical School, Padova, Italy
    Autoimmun Rev 12:832-4. 2013
  9. doi request reprint Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results
    V Pengo
    Department of Clinical Cardiology, Thrombosis Centre, University of Padua, Padua, Italy
    J Thromb Haemost 10:1979-87. 2012
  10. doi request reprint Interpretation of laboratory data and need for reference laboratories
    V Pengo
    Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Italy
    Lupus 21:732-3. 2012

Detail Information

Publications73

  1. ncbi request reprint Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Centre, University of Padova School of Medicine, Ex Busonera Hospital, Via Gattamelata 64, I 35128 Padova, Italy
    Thromb Res 120:127-33. 2007
    ..Nonetheless the high variability of reported data remains a major problem that only a consensus on the part of laboratories and manufacturers to utilize standard, uniform materials and procedures can hope to overcome...
  2. ncbi request reprint The diagnosis of the antiphospholipid syndrome
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Center, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy
    Pathophysiol Haemost Thromb 35:175-80. 2006
    ..In the near future, coagulation tests discriminating between a beta2-GPI and anti-prothrombin LAC may be useful in identifying high risk patients...
  3. ncbi request reprint Sex and anticoagulation in patients with idiopathic venous thromboembolism
    Vittorio Pengo
    Department of Cardiothoracic and Vascular Sciences, University of Padua 35128, Italy
    Lancet 368:342-3. 2006
  4. ncbi request reprint Monitoring oral anticoagulants: new strategies for an emerging problem
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    Intern Emerg Med 1:3-4. 2006
  5. ncbi request reprint The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism
    James D Douketis
    McMaster University, Hamilton, Ontario, Canada
    Ann Intern Med 147:766-74. 2007
    ..The long-term risk for fatal pulmonary embolism (PE) after treatment of venous thromboembolism (VTE) may be an important factor in the decision to discontinue this treatment...
  6. doi request reprint Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile
    V Pengo
    Clinical Cardiology, Thrombosis Center, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    J Thromb Haemost 11:1527-31. 2013
    ..Consequently, classification of patient risk and adequacy of treatment may be deferred by 3 months...
  7. doi request reprint Investigational anticoagulants for hematological conditions: a new generation of therapies
    Gentian Denas
    Padua University Hospital, Cardiology Clinic, Department of Cardiac, Thoracic, and Vascular Sciences, Via Giustiniani 2, 35128 Padova, Italy 390498215658 390498215658
    Expert Opin Investig Drugs 22:1281-94. 2013
    ..The complexity of the coagulation cascade offers interesting inhibition choices that might become valid treatment options...
  8. doi request reprint Correct laboratory approach to APS diagnosis and monitoring
    V Pengo
    Department of Cardiac, Thoracic and Vascular Sciences, University of Padova Medical School, Padova, Italy
    Autoimmun Rev 12:832-4. 2013
    ..Thus, very different risk categories exist among patients with APS as well as among carriers of aPL. Clinical studies and interventional trials should first take these high risk subjects into consideration...
  9. doi request reprint Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results
    V Pengo
    Department of Clinical Cardiology, Thrombosis Centre, University of Padua, Padua, Italy
    J Thromb Haemost 10:1979-87. 2012
    ..Apixaban significantly reduced mortality from any cause. The choice of a new oral anticoagulant should take into account these and other differences between the new drugs...
  10. doi request reprint Interpretation of laboratory data and need for reference laboratories
    V Pengo
    Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Italy
    Lupus 21:732-3. 2012
    ..Monoclonal antibodies against Domain I with Lupus Anticoagulant activity might be candidate material for standardization of antiphospholipid assays. Much work remains to be done in this field...
  11. doi request reprint Secondary prevention in thrombotic antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    Lupus 21:734-5. 2012
    ..The duration of treatment is usually indefinite because of a substantial risk of recurrence...
  12. doi request reprint What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?
    Vittorio Pengo
    Department of Cardiac, Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova Medical School, Padua, Italy
    Semin Thromb Hemost 38:322-7. 2012
    ..Triple positivity apparently identifies the pathogenic autoantibody (antidomain I-II of β2-glycoptrotein I); it is in this category of patients that trials on new therapeutic strategies should focus...
  13. ncbi request reprint Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LI
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Centre, University of Padova, Italy
    Clin Appl Thromb Hemost 13:241-8. 2007
    ..9 to 10.7) in Group A and 4.3% (95% CI 0.2 to 8.4) in Group B (p=0.6). Low-intensity treatment plus aspirin during the first six months after surgery appears to be as effective and safe as moderate-high-intensity anticoagulation...
  14. ncbi request reprint Anti-beta2-glycoprotein I antibody testing in the laboratory diagnosis of antiphospholipid syndrome
    V Pengo
    Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Center, University of Padua School of Medicine, Padua, Italy
    J Thromb Haemost 3:1158-9. 2005
  15. ncbi request reprint Antibody profiles for the diagnosis of antiphospholipid syndrome
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova School of Medicine, Ex Busonera Hospital, Via Gattamelata 64, 1 35128 Padova, Italy
    Thromb Haemost 93:1147-52. 2005
    ..As compared to a single test, the analysis of a complete antiphospholipid antibody profile can better determine patients at risk...
  16. ncbi request reprint Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples
    V Pengo
    Clinical Cardiology, Thrombosis Centre, University Hospital, Padova, Italy
    J Thromb Haemost 5:925-30. 2007
    ..To determine whether the diagnosis of lupus anticoagulant (LAC) in a large cohort of positive patients was confirmed at a reference laboratory...
  17. ncbi request reprint New trends in anticoagulant treatments
    V Pengo
    Clinical Cardiology, Thrombosis Centre, University of Padua School of Medicine, Padua, Italy
    Lupus 14:789-93. 2005
    ..There is no need for laboratory control, and phase II and phase III studies are encouraging. Thus, in the next few years, we may witness great changes in the treatment of patients with thromboembolic disorders...
  18. ncbi request reprint From acute pulmonary embolism to chronic thromboembolic pulmonary hypertension
    Vittorio Pengo
    Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, School of Medicine, Padua, Italy
    Ital Heart J 6:830-3. 2005
    ..This procedure may be difficult when distal branches of pulmonary vascular tree are involved. In selected cases, alternative therapies may be the arterial pulmonary vessel angioplasty and lung transplantation...
  19. doi request reprint Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Thrombosis Center, University Hospital, Padova, Italy
    J Thromb Haemost 8:237-42. 2010
    ..The characteristics and the clinical course of antiphospholipid syndrome (APS) in high-risk patients that are positive for all three recommended tests that detect the presence of antiphospholipid (aPL) antibodies have not been described...
  20. doi request reprint Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis
    V Pengo
    Clinical Cardiology, Thrombosis Center, University Hospital, 35128 Padova, Italy
    J Thromb Haemost 7:1737-40. 2009
    ..Calculation of cut-off values for each diagnostic step are clearly stated. A final paragraph reports the interpretation of the results in general and in particular situations...
  21. ncbi request reprint Worldwide management of oral anticoagulant therapy: the ISAM study
    Vittorio Pengo
    Clinical Cardiology, Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua School of Medicine, Padua 35128, Italy
    J Thromb Thrombolysis 21:73-7. 2006
    ..Studying of anticoagulation management based on local models of care highlights important discrepancies among countries and suggests further standardization of the management of this important therapy is necessary...
  22. ncbi request reprint Management of oral anticoagulant treatment in patients with venous thromboembolism
    Vittorio Pengo
    Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, Padua University, Italy
    Semin Thromb Hemost 32:781-6. 2006
    ..The management of patients with VTE, as well as that of other patients receiving OAT, includes medical controls and expertise that are better available in specialized centers (anticoagulation clinics)...
  23. doi request reprint Antibodies to oxidized LDL/beta2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism
    V Pengo
    Department of Cardio Thoracic and Vascular Sciences, Clinical Cardiology, Italy
    Thromb Res 122:556-9. 2008
    ..Data from this study do not support the hypothesis that IgG anti-oxLDL/beta2GPI are specifically associated to arterial TE in Category I APS patients...
  24. doi request reprint Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation
    V Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova School of Medicine, Via Giustiniani 2, 35128 Padova, Italy
    Thromb Haemost 103:442-9. 2010
    ..5-2.0). However, further trials are needed to confirm the hypothesis generated by the present study...
  25. doi request reprint Antiphospholipid syndrome: critical analysis of the diagnostic path
    V Pengo
    Clinical Cardiology, Thrombosis Centre, University of Padova, School of Medicine, Padova, Italy
    Lupus 19:428-31. 2010
    ..Conversely, all three positive tests identify a single class of abeta2GPI antibodies, thus identifying high-risk patients with APS...
  26. doi request reprint Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA)
    V Pengo
    Clinical Cardiology, Thrombosis Center, Padova, Italy
    Thromb Haemost 106:868-76. 2011
    ..In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with...
  27. ncbi request reprint [Prevention of thromboembolism in non-rheumatic atrial fibrillation: an update]
    V Pengo
    Dipartimento di Medicina Clinica e Sperimentale, Universita degli Studi, Ospedale Ex Busonera Via Gattamelata, 64 35128 Padova
    Ital Heart J Suppl 2:972-9. 2001
    ..New antithrombotic regimens will be tested in the near future...
  28. ncbi request reprint [Current management of oral anticoagulant treatment]
    Vittorio Pengo
    Clinica Cardiologica, Centro Trombosi, Universita degli Studi, Ospedale Ex Busonera Via Gattamelata, 64, 35128 Padova
    Ital Heart J Suppl 3:502-17. 2002
    ..In this review, together with basic knowledge, data from medical literature are used to provide guidelines and practical information for the management of these patients...
  29. doi request reprint APS--controversies in diagnosis and management, critical overview of current guidelines
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova School of Medicine, Padova, Italy
    Thromb Res 127:S51-2. 2011
    ..Clinical studies on groups of patients that are homogeneous in terms of laboratory tests will provide information on the real risk of patients and on the real effect of therapeutic interventions...
  30. ncbi request reprint Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation
    Vittomo Pengo
    Clinical Cardiology, Thrombosis Centre, Padova, Italy
    Am J Cardiol 90:545-7. 2002
  31. ncbi request reprint Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment
    Vittorio Pengo
    Clinica Cardiologica, Centro Trombosi, Universita di Padova, Ospedale Ex Busonera via Gattamelata 64, I 35128 Padova, Italy
    Thromb Haemost 89:760-4. 2003
    ..These data suggest that low intensity anticoagulation, as performed in an anticoagulation clinic, is effective and safe in high risk patients with MS and AF...
  32. doi request reprint Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study
    V Pengo
    Clinical Cardiology, Thrombosis Center, Department of Cardiothoracic and Vascular Sciences, University of Padova School of Medicine, Via Giustiniani 2, 35128 Padova, Italy
    Circulation 119:2920-7. 2009
    ..This prospective inception cohort management study was designed to assess the efficacy and safety of an individualized bridging protocol applied to outpatients...
  33. doi request reprint Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
    Vittorio Pengo
    Departments of Clinical Cardiology, University Hospital, Padova, Italy
    Blood 118:4714-8. 2011
    ..These data can help in the decision to initiate primary thromboprophylaxis in these subjects...
  34. ncbi request reprint A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants
    V Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova School of Medicine, Padova, Italy
    J Thromb Haemost 2:702-7. 2004
    ..Therefore, when a PL-dependent coagulation test is run twice, at different final calcium concentrations, antibeta(2)GPI LA can be identified...
  35. doi request reprint Long-term use of vitamin K antagonists and incidence of cancer: a population-based study
    Vittorio Pengo
    Department of Cardiothoracic and Vascular Sciences, Division of Clinical Cardiology, Universita di Padova, School of Medicine, Via Giustiniani 2, Padua, Italy
    Blood 117:1707-9. 2011
    ..07 (95% CI 0.92-1.24) and 1.12 (95% CI 1.05-1.19), respectively. These results support the hypothesis that anticoagulation might have a protective effect on cancer development, especially prostate cancer...
  36. doi request reprint Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA)
    V Pengo
    Clinical Cardiology, Thrombosis Centre, University Hospital, Padova
    Thromb Res 126:150-3. 2010
    ..The aim of this study was to determine their presence and association with thromboembolic events in a large series of patients with confirmed LA...
  37. doi request reprint Cancer prevention and vitamin K antagonists: an overview
    Vittorio Pengo
    Department of Cardiac Thoracic and Vascular Sciences, Division of Clinical Cardiology, Clinical Medicine, University of Padova, Padova, Italy
    Thromb Res 125:S103-5. 2010
    ....
  38. ncbi request reprint New trends in anticoagulant therapy
    Vittorio Pengo
    Department of Clinical Cardiology, Thrombosis Centre, University of Padua School of Medicine, Padua, Italy
    Isr Med Assoc J 6:479-81. 2004
    ..There is no need for laboratory control and phase II and phase III studies are encouraging. The next few years should bring great changes to the treatment of patients with thromboembolic disorders...
  39. ncbi request reprint Long-term warfarin use to prevent both stroke and dementia in subjects with atrial fibrillation?
    V Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova School of Medicine, Padova, Italy
    J Thromb Haemost 2:1871-2. 2004
  40. ncbi request reprint Antithrombotic strategies for atrial fibrillation: on the threshold of changes? No
    V Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova, School of Medicine, Padova, Italy
    J Thromb Haemost 3:433-5. 2005
  41. doi request reprint Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy
    A Ruffatti
    Department of Clinical and Experimental Medicine, University of Padua, Italy
    Thromb Res 123:482-7. 2009
    ..A relationship between antibody profile and pregnancy outcome in patients with a previous diagnosis of primary antiphospholipid syndrome (APS) has not been clearly documented...
  42. ncbi request reprint Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins
    P Rampazzo
    Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova, Italy
    Thromb Haemost 85:57-62. 2001
    ..In conclusion, some patients with APS harbor circulating antibodies to other CL-binding proteins which might be useful to further characterize these patients...
  43. doi request reprint Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome
    A Ruffatti
    University of Padua, Padua, Italy
    Arthritis Care Res (Hoboken) 62:302-7. 2010
    ..To evaluate the relationship between the antiphospholipid profile and clinical characteristics of pregnant women with antiphospholipid syndrome (APS) and neonatal outcome...
  44. doi request reprint Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification
    A Ruffatti
    Rheumatology Unit, University of Padua, Padua, Padova, Italy
    J Thromb Haemost 6:1693-6. 2008
    ....
  45. ncbi request reprint Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity
    V Pengo
    Department of Clinical and Experimental Medicine, Thrombosis Center, The Department of Laboratory Medicine, and the Department of Oncology and Surgical Sciences, University of Padova School of Medicine, Padova, Italy
    Blood 94:3814-9. 1999
    ..These results show that abeta2-GPI antibodies exhibit an 'in vitro' procoagulant effect in PT and an anticoagulant effect in dRVVT only when the interaction with their antigen and PL occurs in the absence of calcium ions...
  46. ncbi request reprint dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies
    V Pengo
    Dept of Cardiology, Thrombosis Center, University of Padova School of Medicine, Italy
    Thromb Haemost 81:256-8. 1999
    ..31 and 1.49 at a PLs dilution of 1:8 and 1:64, respectively. Therefore, the presence of LA activity due to autoantibodies to beta2-GPI is characterized by a positive dRVVT and negative or only weakly positive KCT and TTI...
  47. ncbi request reprint Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study
    A Ruffatti
    University of Padova, Padova, Italy
    Lupus 14:120-8. 2005
    ....
  48. ncbi request reprint Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study
    V Pengo
    Department of Clinical and Experimental Medicine, University of Padova, Italy
    Thromb Haemost 85:418-22. 2001
    ..Patients were kept at optimal intensity of treatment for 63% of the time. These data confirm the efficacy of OA but identify elderly patients as a high risk group of major bleeding...
  49. ncbi request reprint Oral anticoagulant treatment in very elderly patients with atrial fibrillation
    V Pengo
    Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova School of Medicine, Ex Busonera Hospital, Via Gattamelata, 64 I-35128 Padova, Italy
    Compr Ther 27:7-10. 2001
    ..Therefore, a systemic approach in which the thromboembolic and hemorrhagic risk profiles are taken into account is suggested...
  50. ncbi request reprint Effect of anti-beta2glycoprotein I Lupus Anticoagulants on fibrin polymerization and fibrinolysis
    V Pengo
    Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova School of Medicine, Ex Busonera Hospital, Italy
    Autoimmunity 32:39-44. 2000
    ..These data provide evidence that anti-beta2GPI LA may act as either anticoagulants or procoagulants in different in vitro coagulation tests...
  51. ncbi request reprint Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis
    P Prandoni
    Department of Medical and Surgical Sciences, University Hospital of Padua, Padua, Italy
    J Thromb Haemost 4:1891-6. 2006
    ..We hypothesized that patients with VTE of unknown origin would be at a higher risk of developing symptomatic atherosclerosis than patients with VTE induced by known risk factors...
  52. ncbi request reprint Difference in mortality after hip fracture is associated with postdischarge prescription of antithrombotic prophylaxis: a case-control study
    Anna Maria Grion
    Servizio Farmaceutico, Centro Trombosi, Universita di Padova, Italy
    Clin Appl Thromb Hemost 8:143-6. 2002
    ..03-0.73; p=0.011). Patients admitted to the hospital for hip fracture are at high risk of death after discharge if they are not given antithrombotic treatment. To substantiate these data, ad hoc prospective randomized trials are needed...
  53. ncbi request reprint Oral anticoagulant therapy in patients with atrial fibrillation
    Vittorio Pengo
    Department of Clinical Cardiology, Thrombosis Centre, University of Padova, Italy
    Semin Vasc Med 3:333-8. 2003
    ..Because age of more than 75 years is a major risk factor for stroke, but is also a risk factor for major bleeding, the decision to treat elderly patients with anticoagulants should be made on an individual basis...
  54. ncbi request reprint Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism
    Vittorio Pengo
    Department of Clinical and Experimental Medicine, Division of Clinical Cardiology, University Hospital of Padua, Padua, Italy
    N Engl J Med 350:2257-64. 2004
    ..Chronic thromboembolic pulmonary hypertension (CTPH) is associated with considerable morbidity and mortality. Its incidence after pulmonary embolism and associated risk factors are not well documented...
  55. ncbi request reprint Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity
    Amelia Ruffatti
    Department of Clinical and Experimental Medicine, Division of Rheumatology, University of Padua, Italy
    Thromb Haemost 96:337-41. 2006
    ..Triple positivity and/or a history of thromboembolism predict new TE events and new unsuccessful pregnancies...
  56. ncbi request reprint A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova School of Medicine, Ex Busonera Hospital, Via Gattamelata 64, I 35128 Padova, Italy
    Am J Clin Pathol 120:944-7. 2003
    ..For patients in stable condition with a prosthetic heart valve who are monitored at an anticoagulation clinic, a 6-week interval between INR determinations does not increase the biologic risk of thromboembolic or hemorrhagic events...
  57. ncbi request reprint Mechanical prosthetic heart valve thrombosis despite optimal anticoagulation in a patient with congenital thrombophilia (factor V Leiden)
    Cinzia Pegoraro
    Clinical Cardiology, Thrombosis Center, University of Padova, Italy
    Clin Appl Thromb Hemost 9:89-90. 2003
    ..The intensity of warfarin anticoagulation was increased to provide more protection for the patient...
  58. ncbi request reprint Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
    Maria Gabriella Scordo
    Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy
    Clin Pharmacol Ther 72:702-10. 2002
    ..Our objective was to determine the influence of cytochrome P450 (CYP) 2C9 and CYP2C19 genetic polymorphisms on warfarin dose requirement and metabolic clearance...
  59. ncbi request reprint Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity
    Armando Tripodi
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, University and IRCCS Maggiore Hospital, 20122 Milan, Italy
    Clin Chem 49:1608-14. 2003
    ..The control plasmas used in these surveys were from LA-positive or -negative patients or were normal plasmas with monoclonal antibodies against human beta(2)-glycoprotein I (beta(2)-GPI) added...
  60. ncbi request reprint Risks factors for highly unstable response to oral anticoagulation: a case-control study
    Gualtiero Palareti
    Dipartimento di Angiologia e Malattie della Coagulazione Marino Golinelli, Policlinico S Orsola Malpighi, Universita di Bologna, Bologna, Italy
    Br J Haematol 129:72-8. 2005
    ..9% vs.15.0%; P = 0.042). No differences were observed as regards the other variables. In conclusion, we found that high intra-individual variability in OAT control was multifactorial, but poor OAT comprehension was prevalent...
  61. ncbi request reprint Interventional approach to reduce thromboembolic risk in patients with atrial fibrillation ineligible for oral anticoagulation
    Angelo Ramondo
    Department of Pharmacology and Anesthesiology, Egidio Meneghetti, University of Padua, Padua, Italy
    Ital Heart J 6:414-7. 2005
    ..In conclusion, the interventional approach in patients with atrial fibrillation ineligible for oral anticoagulation seems feasible and promising, and deserves further investigation...
  62. ncbi request reprint The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients
    Paolo Prandoni
    Department of Medical and Surgical Sciences, University of Padua, Via Ospedale Civile 105, 35128, Padua, Italy
    Haematologica 92:199-205. 2007
    ..The aim of this investigation was to assess the rate of recurrent VTE after withdrawal of vitamin K antagonists, and to identify clinical parameters associated with a higher likelihood of recurrence...
  63. ncbi request reprint Apolipoprotein E (APOE) and warfarin dosing in an Italian population
    Hugo Kohnke
    Eur J Clin Pharmacol 61:781-3. 2005
  64. ncbi request reprint Knowledges about herbal products among subjects on warfarin therapy and patient-physician relationship: a pilot study
    Laura Cuzzolin
    Department of Medicine and Public Health, Section of Pharmacology, University of Verona, Italy
    Pharmacoepidemiol Drug Saf 16:1014-7. 2007
    ..The purpose of our study was to analyse behaviours and patient-physician relationship about phytotherapy among a sample of Italian patients on warfarin therapy for atrial fibrillation...
  65. ncbi request reprint Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM)
    Jack Ansell
    Department of Medicine, E113, Boston University Medical Center, 88 E Newton St, Boston, MA, 02118, USA
    J Thromb Thrombolysis 23:83-91. 2007
    ....
  66. ncbi request reprint Thrombophilia in young patients with cryptogenic stroke and patent foramen ovale (PFO)
    Pietro Offelli
    Clinical Cardiology, Thrombosis Centre, University Hospital, Padova, Italy
    Thromb Haemost 98:906-7. 2007
  67. ncbi request reprint A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without
    Vittorio Pengo
    Arterioscler Thromb Vasc Biol 27:e309-10. 2007
  68. ncbi request reprint Classification of patients with antiphospholipid syndrome into risk categories: an evolving process
    Vittorio Pengo
    Thromb Haemost 96:855-6. 2006
  69. ncbi request reprint D-dimer testing to determine the duration of anticoagulation therapy
    Gualtiero Palareti
    Department of Angiology and Blood Coagulation, S Orsola Malpighi University Hospital, Bologna, Italy
    N Engl J Med 355:1780-9. 2006
    ..The optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism is uncertain. Testing of D-dimer levels may play a role in the assessment of the need for prolonged anticoagulation...
  70. ncbi request reprint Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome
    Panagiotis Grypiotis
    Rheumatology Unit, University of Padova, Padova, Italy
    J Clin Lab Anal 20:15-8. 2006
    ..Moreover, the highest sensitivity was reached with a combination of SCT and dRVVT. The method's association with total thrombotic events and venous thrombosis was in fact significant...
  71. ncbi request reprint Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature
    Amelia Ruffatti
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    Autoimmun Rev 6:196-202. 2007
    ..Further studies in this type of patients are certainly warranted...
  72. ncbi request reprint Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
    Harumi Takahashi
    Department of Pharmacotherapy, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan
    Pharmacogenet Genomics 16:101-10. 2006
    ....
  73. ncbi request reprint Features associated with epilepsy in the antiphospholipid syndrome
    Yehuda Shoenfeld
    Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel
    J Rheumatol 31:1344-8. 2004
    ....